GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Other Current Payables

Kyverna Therapeutics (Kyverna Therapeutics) Other Current Payables : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Other Current Payables?

Kyverna Therapeutics's Other Current Payables for the quarter that ended in Mar. 2024 was $0.00 Mil.


Kyverna Therapeutics Other Current Payables Historical Data

The historical data trend for Kyverna Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Other Current Payables Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Other Current Payables
- - -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Other Current Payables Get a 7-Day Free Trial - - - - -

Kyverna Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Kyverna Therapeutics Other Current Payables Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines